CD45 Universal CAR T / Cimeio Therap, University of Pennsylvania - LARVOL DELTA

Cimeio Therapeutics Announces Research Collaboration With the University of Pennsylvania to Conduct Preclinical Studies of a CD45 Universal CAR T Cell Therapy for Patients With Blood and Bone Marrow Cancers (Businesswire) - "Cimeio Therapeutics today announced a preclinical research collaboration with Saar Gill, M.D., Ph.D., an associate professor of medicine and a researcher in the Center for Cellular Immunotherapies in the Perelman School of Medicine at the University of Pennsylvania, to research and evaluate a novel universal immunotherapy with potential to treat multiple blood and bone marrow cancers. The Penn team will combine Cimeio Therapeutics’ proprietary epitope-editing and CD45-targeting technologies with Penn Medicine’s epitope-editing and CAR T cell technology to create a CD45-targeting CAR T cell therapy and paired epitope-edited hematopoietic stem cell (HSC).... The company plans to develop that therapy with CD45 epitope shielded cells for blood cancers and autoimmune diseases among other indications."

Licensing / partnership • Hematological Malignancies • Oncology